Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Stage IV Prostate Cancer AJCC v8: early-phase trial registry
15 of 29 indexed Stage IV Prostate Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #552 of 28,707 conditions by registered trial count.
29 US clinical trials · 15 currently recruiting · #552 of 28,707 conditions by registered trial count
Stage IV Prostate Cancer AJCC v8: 29 US clinical trials tracked, 15 recruiting.
Stage IV Prostate Cancer AJCC v8 is the subject of 29 registered US clinical trials on ClinicalTrials.gov, 15 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 24 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition stage-iv-prostate-cancer-ajcc-v8
OPEN 15 | RECR 52% | LATE 3 | EARLY 24 | RANK #552 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Kidney Stone (52% recruiting · 29 trials)
Stage IV Prostate Cancer AJCC v8 lists 15 open slots (52% of 29 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Stage IV Prostate Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Stage IV Prostate Cancer AJCC v8 is recruiting above its size-band peers.
15 of 29 indexed trials (51.7%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Stage IV Prostate Cancer AJCC v8 research.
M.D. Anderson Cancer Center accounts for 6 of 29 trials (20.7%). 14 distinct sponsors appear on at least one study for this condition label.
-
Most Stage IV Prostate Cancer AJCC v8 trials plan to enrol fewer than 100 people.
Median target enrolment is 70 among the 29 trials that report a genuine target (sentinel values excluded). 19 of those (65.5%) plan for fewer than 100 participants.
-
Stage IV Prostate Cancer AJCC v8 research is mostly interventional.
28 interventional and 1 observational studies make up this index (96.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
29 total, page 1 of 1
Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
SWOG Cancer Research Network
NCT03678025
Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
Mayo Clinic
NCT05045066
Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
City of Hope Medical Center
NCT05869682
Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
M.D. Anderson Cancer Center
NCT05054296
Peer Navigation for the Support of Metastatic Prostate Cancer Patients Undergoing Genetic Evaluation
Thomas Jefferson University
NCT05487846
SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
Mayo Clinic
NCT06205316
Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer With Rising PSA After Radical Prostatectomy
Jonsson Comprehensive Cancer Center
NCT04915508
Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
University of California, Davis
NCT06173362
Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
City of Hope Medical Center
NCT04734730
Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer
Mayo Clinic
NCT07073794
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
University of Utah
NCT05168618
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
NCT05691465
Abemaciclib Before 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
Vadim S Koshkin
NCT05113537
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Mayo Clinic
NCT07025369
Extending Prostate Genetic Awareness, Navigation, and Delivery: The EXPAND Network
Thomas Jefferson University
NCT05627219
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
NCT03217747
Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT04592237
A Study to Evaluate Hypofractionated Proton Therapy or IMRT for Recurrent, Oligometastatic Prostate Cancer
Mayo Clinic
NCT04190446
Testing Interruption of Hormonal Medications in Patients Responding Exceptionally to Therapy for Metastatic Prostate Cancer, (A-DREAM)
Alliance for Clinical Trials in Oncology
NCT05241860
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
National Cancer Institute (NCI)
NCT03517969
DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers
M.D. Anderson Cancer Center
NCT04388852
A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy
Alliance for Clinical Trials in Oncology
NCT04455750
ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
Rahul Aggarwal
NCT04471974
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
NCT03821792
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
Thomas Hope
NCT04716725
PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer
City of Hope Medical Center
NCT03873805
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
NCT05960578
68GA-PSMA-11 PET/CT Scan in Impacting Treatment Strategies for Patients With Prostate Cancer
Jonsson Comprehensive Cancer Center
NCT04050215
Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
NCT03204812
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
| Phase 2 | 19 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Stage IV Prostate Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Stage IV Prostate Cancer AJCC v8 trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Stage IV Prostate Cancer AJCC v8 page
29 registered trials, 15 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 15 Stage IV Prostate Cancer AJCC v8 trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Stage IV Prostate Cancer AJCC v8 trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage IV Prostate Cancer AJCC v8 condition card totals 29 registered trials; most-linked intervention Questionnaire Administration; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.